Grant: Planning and Dissemination Grant - Institute Community Support

GLP-1 and GIP medications, used to treat type 2 diabetes and obesity, help control blood sugar, reduce appetite, and promote significant weight loss (5-15% of body weight), while also lowering heart disease and kidney risks. These drugs work by mimicking a gut hormone that boosts insulin, slows digestion, and signals fullness to the brain, improving health markers like blood pressure and cholesterol. However, their use can reduce food intake, raising concerns about getting enough protein and nutrients to maintain muscle, especially in older adults, where muscle loss may increase weakness. Many people regain weight after stopping these medications, highlighting the need for lasting diet and lifestyle changes. Access to these costly drugs is also a challenge, with many unable to afford them, creating unfair gaps in care. This one-day conference will bring together experts, patients, and clinicians to explore ways to improve nutrition, prevent muscle loss, and sustain weight loss while ensuring everyone can access these life-changing treatments. By sharing the latest research and practical solutions, this conference conference aims to help people with type 2 diabetes and obesity live healthier lives.